Yogen Saunthararajah
3 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies (NCT02846935) | Yogen Saunthararajah | 2017-04-25 |
| p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer (NCT02847000) | Yogen Saunthararajah | 2016-12-20 |
| Study of Decitabine and Tetrahydrouridine (THU) in Patients With Sickle Cell Disease (NCT01685515) | Yogen Saunthararajah | 2012-08-01 |
Track Yogen Saunthararajah automatically
Every clearance here is in the API, with alerts when new ones post.